Indicator full name: Incidence of cancer per 100 000, female
Unit: cases per 100 000 population
- Country (COUNTRY)
- Supranational group of countries (COUNTRY_GRP)
- Sex (SEX)
- Year of measure (YEAR)
Years data is available: 1970—2016
Last updated: 17 October 2019
- WHO European Region
- Members of the European Union
- Members of the EU before May 2004 (EU15)
- Members of the EU after May 2004 (EU13)
- Commonwealth of Independent States
- Central Asian Republics Information Network members (CARINFONET)
- South-eastern Europe Health Network members (SEEHN)
- Nordic countries
- Small countries
The following abbreviations are used in the indicator titles:
The joint monitoring framework (JMF) is used for reporting on indicators under three monitoring frameworks: the Sustainable Development Goals (SDGs), Health 2020 and the Global Action Plan for the Prevention and Control of Noncommunicable Diseases (NCDs) 2013–2020. The Regional Committee for Europe adopted the JMF in September 2018.
The majority of JMF indicators in the Gateway are linked to existing databases in the Gateway.
EUR/RC68/10 Rev.1 Briefing note on the expert group deliberations and recommended common set of indicators for a joint monitoring framework
EUR/RC68(1): Joint monitoring framework in the context of the roadmap to implement the 2030 Agenda for Sustainable Development, building on Health 2020, the European policy for health and well-being
Developing a common set of indicators for the joint monitoring framework for SDGs, Health 2020 and the Global NCD Action Plan (2017)
Indicator code: E991001.F This indicator shares the definition with the parent indicator \"Number of new cases of cancer\".
Number of patients with newly diagnosed cancer during given calendar year. Usually data sources are national cancer registers or the existing routine reporting system of health establishments. In the latter case, data are expected to be less accurate than register data._
Armenia http://moh.am/?section=static_pages/index&id=625&subID=824,29. Data collected annually,
reference period: 31 December.
The cancer register includes only malignant neoplasms (benign cases are not registered). In
accordance with IARC definitions, the date of diagnosis is used as the date of incidence.
Data source: National Cancer Register (http://www.kankerregister.org/). Data before the year 2004
were incomplete and should be used with caution.
Institute of Federation of B&H ; Cancer Register
Public Health Institute of Republic of Srpska ; Cancer Register established 2001.
Department for Health of Brcko District
Certificate Only are also included in all years (1998-2007).
In the Czech Republic, the data include malignant neoplasms, in situ neoplasms and neoplasms of
uncertain or unknown behaviour (C00-C97, D00-D09, D37-D48).
Data from 1990 updated.
According to the recommendations of the International Association of Cancer Registries, the Estonian
Cancer Registry presents cancer incidence data not sooner than two years after the end of a
corresponding calendar year. Incidence data have been updated on the basis of the Registry?s
database in January 2016.
Institute for Health and Welfare).
Source: Cancer Register, THL (National Institute for Health and Welfare) / Cancer Organizations.
par cancer en France entre 1980 et 2012
Due to reform in 2011, the data may show inconsistency.
http://www.krebsdaten.de or http://www.rki.de
Coverage: Data contain the estimated number of all newly diagnosed cancer cases in Germany coded
with ICD-10 C00-C97 (Malignant neoplasms) excluding ICD-10 C44 (Other malignant neoplasms of skin)
during the given calendar year.
Estimation method: The population-based cancer registries in each German federal state transfer data
to the German Centre for Cancer Registry Data (ZfKD), as required by the Federal Cancer Registry
Data Act (Bundeskrebsregisterdatengesetz). These data are combined, quality-checked, analysed and
At the moment reliable data on cancer incidence and survival are not available for all federal
states. Therefore, the ZfKD estimates new diagnosis, prevalence and survival rates for Germany in
addition to estimating the completeness of data capture in the individual registries. The basic
principle is that the data are first checked for registration completeness and, upon meeting
pre-defined criteria, are then used for the calculation of the various statistics.
The value of population-based cancer data vitally depends on the completeness of the capture of all
newly diagnosed cancer cases. Since 2009 in all federal states there has been comprehensive
geographical epidemiological cancer registration and great advances have been achieved. But the
situation in the individual states is very heterogeneous: continuous, state-wide registration was
commenced between 1967 (Saarland) and 2009 (Baden-Wurttemberg). The ZfKD consequently regularly
estimates the degree of completeness for the population-based cancer registries.
The basis for this evaluation is the ratio of incidence to mortality (M/I-Index), an internationally
commonly used indicator. It is assumed here that diagnosis and survival prospects of cancer patients
within Germany do not differ fundamentally and that regionally differing cancer risks can thus be
approximated by official cause of death statistics. Using the M/I-Index of a reference registry that
has been assessed as being complete along with the cancer mortality at a region whose completeness
is to be assessed, it is possible to estimate the expected cancer incidence in that region and
compare it with the number of cases actually registered.
According to the current evaluation, for the year 2012, twelve federal states have already reached
an estimated completeness level of at least 90%, seven federal states have reached over 95%
Using the data of the epidemiological cancer registries in Germany as a basis, the ZfKD estimates
the number of all newly diagnosed cancer cases each year. The results of the completeness assessment
form the basis of this estimation. The annual number of incident cases for each localization arises
from the summation of the cases from the ?complete? registries (estimated capture rate of at least
90%) and the expected incidence from the completeness assessment for those federal states that are
either deemed to be incomplete or for which no data is available.
Break in time series: The modification of the procedure to estimate completeness required the
adaption of the methods for estimating incidence. One of the requirements places on the new method
was to enable a smooth transition from ?estimating? to ?counting? the annual number of incident
cases in Germany while continuing to allow an assessment of trends over time. Since the new methods
of estimation for both completeness and incidence can only be used in this form from 1999 onwards,
the results of earlier estimates are not directly comparable to the current ones for methodological
Note: Benign tumours are rarely registered in the NCR. Some data from 1999 were recorded as year
2000. Correction of the data has only partially taken place. Therefore, there is a higher case
number in 2000. Data for the number of metastatic tumours with codes C77-C79 have been left out.
non-melanoma skin cancer.
Note: Figures for the latest year are incomplete and should be considered provisional. Numbers
indicate number of newly diagnosed cancers rather than patients. Each new primary tumour is counted
? so for example if an individual patient was diagnosed with a primary breast and a primary cervical
cancer in 2012, they are represented by 2 tumours in the ?number of all cancers? (and not just as 1
Centro Nazionale di Epidemiologia Sorveglianza e Prevenzione della Salute (ISS, CNESPS). Estimates
were obtained with the MIAMOD methodology using cancer-specific mortality 1970-2002 (Official
National Statistics - ISTAT) and survival of patients diagnosed in 1985-2002 (Italian Network of
Cancer Registries - AIRTUM). The MIAMOD method was applied to obtain forecasts from 2003 onwards .
Cancer-specific estimates were obtained separately by sex for the 20 Italian regions. National
estimates were obtained by summing up the regional estimates. Estimates for all cancers were derived
by summing up the estimated number of new cases for cancers of colon-rectum, lung, stomach, prostate
(males) or breast (females), and for all other cancers combined. All estimates are referred to age
group 0-99 years. For further details see: Rossi S, Capocaccia R, De Angelis R and Gatta G (Eds).
Cancer Burden in Italian Regions. Tumori 2013; 99 (3): pp. 269-439
Break in time series: Up to 2002 the data source was the annual statistical report. Starting from
2003 the data source is the Register of Patients with Particular Diseases.
pathologique, de cytologie clinique et d'hematologie. Annual report edited by the association
\Registre morphologique des tumeurs au Grand-Duche
Pathology labs., Autopsy reports, National Mortality Register and Notification.
The decrease in incidence in 2008 is due to a change in cancer recording policy from 2008 viz.
from this date on wards, non-melanoma skin cancers were not included in the uploaded data.
for new cases of cancer (ICD-10: C00-C97) in 2013.
National Center for Statistics and Informatics in Public Health.
Break in time series:
2014: since year 2014, data from private sector included.
Coverage: complete from 2007 onwards. Up to 2007 data do not cover one NUTS level-2 Region
(Vojvodina) that is approximately 30% of population (according Census 2011 data). Decreasing of
number of new cases starting from 2012 onwards indicates underreporting by health institutions.
The data for 991051:Number of new cases of cancer (incidence), is continuously updated with new
cases of cancer or deaths for each year. The data value can be higher than the data values for
indicator 045601:All cases of cancer (prevalence) because the Slovak Republic provides only
incidence data to IARC (International Agency for Research on Cancer), which then processes them and
provides prevalence data.
Methodology (definition): Number of all newly diagnosed cancers (ICD-10: C00?C96, other malignomas
of skin (C44) is included) that develop in a defined population (residents of the Republic of
Slovenia) in one calendar year. The incidence consider the number of cases of disease not the number
of patients, therefore the same patient can contribute to the incidence number more than one case of
disease, if he/she is diagnosed with more than one different cancers in the same year.
The Swedish Cancer Register (NBHW)
Online Database: http://www.socialstyrelsen.se/statistics/statisticaldatabase/cancer
Observe that the number represents new primary tumors (new cancer cases) during the year. In the
rare event that a person should have two new primary tumors during the same calendar year that
person is counted twice. This may happen for bilateral organs and for all sites collapsed.
ICD7 three digit level. All subgroups on the fourth level (e.g. 162.1, lung cancer) are included.
The specification of tumors included in the register is described in the ordinance SOSFS 2006:15
The description of the official statistics on cancer is included in the Swedish language report.
Cancer incidence in Sweden 2013 (Cancerincidens I Sverige 2013).ÿ
The following text regarding incidence and prevalence relate to cancer-indicators E991051. (M, F,
T), E045601. (M, F, T), E991052. (M, F, T), E105601.F and E105401.F:
-The Swedish cancer register doesn?t apply IARC?s recommendations for multiple primaries
(International rules for multiple primary cancers (ICD-O Third Edition).
This means that the incidence differs from reported incidence from other countries. Especially for
breast cancer the difference is obvious. For example in year 2014 the number of female breast cancer
tumours was 9730 while the number of unique women was 8023.
Incidence and prevalence
-The Swedish cancer registry does not search for and perform follow-back in other registers for
cancer cases identified from death certificates, as the other Nordic cancer registries do. This may
lower Swedish incidence rates.
Registration (NICER) based on the Cancer Registries of Geneva (since 1970), Vaud and Neuchatel
(since 1974), Zurich (1980-2011), St. Gallen-Appenzell (since 1980), Basel-Stadt and
Basel-Landschaft (1981-2009), Valais and Graubunden (since 1989), Glarus (Since 1992), Ticino (Since
1996), Jura (since 2005), Fribourg (since 2006), Lucerne (since 2010), Nidwalden, Obwalden, Uri and
Zug (since 2011).
Coverage: extrapolation based on registered areas covering from 41% of the population in 1980 to 65%
Deviation from the definition: Without non-melanoma skin cancer (C44)
Estimation method: The extrapolation is based on language regions, for detailed information please
refer to the Federal Statistical Office?s Cancer Epidemiology website.
Break in time series:
Cancer registration was launched in Turkey in 1983, when cancer was declared as a notifiable
disease. Later, it was observed this registration system, which was based on passive data
collection, did not prove to be successful enough and active data collection was introduced. Active
cancer registration system, which was launched in 2000, is being implemented in 10 provinces as of
the year 2010. This new system enables collection of complete, qualified and standardized data. In
the active system, data procedures are undertaken by educated staff and trainings are given to
After the active system was introduced, data leakages have been outstandingly diminished and data
completeness has increased to about 98 %. Thanks to the active system, data, which were not
registered previously, were taken under registration. Major increase has been noted in quantity of
data due to the increased availability of diagnostic tests and methods and growth in the elderly
with cancer?, 5 ?Report on morbidity?, 025-2/y ?Statistical card? and 090-1/y ?Notification of
patients with newly diagnosed malignancy?.
Northern Ireland - Northern Ireland Cancer Registry.
Scotland - Scottish Cancer Registry, NHS National Services Scotland, Information Services
Wales - Welsh Cancer Intelligence and Surveillance Unit.
Coverage: (In October 2013) Scotland has revised their time series data due to improvements in data
quality. ?The data has been changed from 2000 onwards as this is more up to date and is our policy
to continually update if it is more accurate.?
Deviation from the Definition: England , Northern Ireland and Scotland figures exclude Non Melanoma
Break in level of trend between 1997 and 1998 may be due to the implementation across country of a
standard definition of incidence date, which is essentially the date of first consultation at or
admission to hospital for the cancer. Previously the cases were allocated to the date of microscopic
verification or the date of starting treatment.
Break in Time Series: 2010 - All data is financial year data with the exception of Scotland and
Northern Ireland whose data is calendar year.
Estimate: 2014 data from Scotland is unavailable so the 2013 figure has been used as an estimate